Hodgkin's lymphoma and CD30 signal transduction

International Journal of Hematology

Volumn 77, Issue 1, 2003, Pages 37-47

  Horie, Ryouichi ^a,b,c   Higashihara, Masaaki ^a   Watanabe, Toshiki ^b  

^a KITASATO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD30; Hodgkin and Reed Sternberg cell; Hodgkin's lymphoma; I B ; NF B

Indexed keywords

CD30 ANTIGEN; I KAPPA B; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; VIRUS PROTEIN;

B LYMPHOCYTE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOCYTE; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD30; HODGKIN DISEASE; HUMANS; NF-KAPPA B; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION;

EID: 0038651209     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982601     Document Type: Review

References (123)

1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17:68-114.
2. Kaufman D, Longo DL. Hodgkin's disease. Crit Rev Oncol Hematol. 1992;13:135-156.
3. Gruss HJ, Kadin ME. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin Haematol. 1996;9: 417-446.
4. Hsu SM, Hsu PL. The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. Crit Rev Oncog. 1994;5:213-245.
5. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495-1505.
6. Cossman J, Annunziata CM, Barash S, et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood. 1999;94: 411-416.
7. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol. 1998;16: 471-493.
8. Brauninger A, Hansmann ML, Strickler JG, et al. Identification of common germinal center-B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med. 1999;340:1239-1247.
9. Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol. 1999;36:233-241.
10. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68:421-427.
11. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982; 299:65-67.
12. Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg Reed cells as a unique cell type derived from a newly detected small-cell population. Int J Cancer. 1982;30:445-459.
13. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
14. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73: 1349-1360.
15. Baker SJ, Reddy EP. Transducers of life and cell death: TNF receptor superfamily and associated proteins. Oncogene. 1996;12:1-9.
16. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962.
17. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378-3404.
18. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
19. Wood KM, Roff M, Hay RT. Defective IκBα in Hodgkin cell lines with constitutively active NFκB. Oncogene. 1998;16:2131-2139.
20. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene. 1999;18:3063-3070.
21. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappa B activity and mutations in I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999;94:3129-3134.
22. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkBa gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-401.
23. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18: 943-953.
24. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed Sternberg cells. Oncogene. 2002;21:2493-2503.
25. Andreesen R, Osterholz J, Lohr GW, Bross KJ. A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts. Blood. 1984;63:1299-1302.
26. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74:1678-1689.
27. Ellis TM, Simms PE, Slivnick DJ, Jäck HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993;151:2380-2389.
28. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caliqaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol. 1995;57:726-730.
29. Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995;9:81-86.
30. Manetti R, Annunziato F, Biagiotti R, et al. CD30 expression by CD8+T cells producing type 2 helper cytokines: evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med. 1994;180:2407-2411.
31. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today. 1995;16:76-80.
32. Hamann D, Hilkens CM, Grogan JL, et al. CD30 expression does not discriminate between Th1- and Th2-type T cells. J Immunol. 1996;156:1387-1391.
33. Alzona M, Jack HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-γ and IL-5 and exhibit enhanced B cell helper activity. J Immunol. 1994;153:2861-2867.
34. Abbondanzo SL, Sato N, Straus SE, Jaffe ES. Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol. 1990;93:698-702.
35. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T-cells. Immunity. 1995;2:587-596.
36. Ohtsuka E, Kikuchi H, Nasu M, Takita-Sonoda Y, Fujii H, Yokoyama S. Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma. 1994;15:303-310.
37. Takeshita M, Akamatsu M, Ohshima K, et al. CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology. 1995;26:539-546.
38. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1-14.
39. Pallesen G. The diagnostic significance of the CD30 (Ki-1) antigen. Histopathology. 1990;16:409-413.
40. Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol. 1996;93:569-571.
41. Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood. 1996;88:3299-3305.
42. Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol. 1996;149:469-448.
43. Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood. 1997;89:2048-2059.
44. Romagnani P, Annunziato F, Manetti R, et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood. 1998;91:3323-3332.
45. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo, I: partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989;19:157-162.
46. Hansen HP, Chiseler T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer. 1995;63:750-756.
47. Pizzolo G, Stein H, Josimovic-Alasevic O, et al. Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms. Br J Haematol. 1990;75:485-488.
48. Pfreundschuh M, Pohl C, Berenbeck C, et al. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer. 1990;45:869-874.
49. Pizzolo G, Vinante F, Nadali G, et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol. 1997; 108:251-253.
50. Dallenbach F, Josimovic-Alasevic O, Durkop H, et al. Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/ leukemia (ATL): a marker for disease activity. In: Knapp W, Dorken B, Gilks WR, et al, eds. Leukocyte Typing IV Oxford, UK: Oxford University Press; 1989:426.
51. Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood. 1998;91: 3011-3016.
52. Zinzani PL, Pileri S, Bernardi M, et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol. 1998;16:1532-1537.
53. Luigi P, Pileri S, Bendandi M, et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol. 1998;16:1532-1537.
54. Maggi E, Annunziato F, Manetti R, et al. Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals. Immunity. 1995;3:251-255.
55. Lee CI, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 1996;183:669-674.
56. Telford WG, Nam SY, Podack ER, Miller RA. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol. 1997;182:125-136.
57. Shanebeck KD, Maliszewski CR, Kennedy MK, et al. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol. 1995;25:2147-2153.
58. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structure and expression of murine CD30 and its role in cytokine production. J Immunol. 1996;156:442-449.
59. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Signaling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 1999;398:341-344.
60. Cerutti A, Schaffer A, Shah S, et al. CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity. 1998;9:247-256.
61. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell. 1996;84:551-562.
62. Gruss HJ, Ulrich D, Dower SK, Herrmann F, Brach MA. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin 6 engaging the NF-κB transcription factor. Blood. 1996;87:2443-2449.
63. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83:2045-2056.
64. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10:457-470.
65. Ghosh S, May MJ, Kopp EB. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
66. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999;18:6867-6874.
67. Miyamoto S, Verma IM. Rel/NF-kappaB/I kappaB story. Adv Cancer Res. 1995;66:255-292.
68. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Ann Rev Cell Biol. 1994;10:405-455.
69. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene. 1999; 18:6845-6852.
70. Baeuerle PA, Baichwal VR. NF-kappaB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol. 1997;65:111-137.
71. Barnes PJ, Karin M. Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336: 1066-1071.
72. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853-6866.
73. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C. Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc Natl Acad Sci U S A. 1999;96:9409-9414.
74. Korner M, Tarantino N, Debre P. Constitutive activation of NF-κB in human thymocytes. Biochem Biophys Res Commun. 1991;181: 80-86.
75. Krishnamoorthy RR, Crawford MJ, Chaturvedi MM, et al. Photooxidative stress down-modulates the activity of nuclear factor-kappaB via involvement of caspase-1, leading to apoptosis of photoreceptor cells. J Biol Chem. 1999;274:3734-3743.
76. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97: 2798-2807.
77. Rayet B, Gelinas C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
78. Staratschek-Jox A, Kotkowski S, Beige G, et al. Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells: no evidence for the persistence of integrated viral fragments in latent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease. Am J Pathol. 2000;156:209-216.
79. Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16:6131-6140.
80. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci USA. 1997;94:12592-12597.
81. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP-1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1997;94:1447-1452.
82. McFarland EDC, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB. Oncogene. 1999;18:6959-6954.
83. Teramoto N, Cao L, Kawasaki N, et al. Variable expression of Epstein-Barr virus latent membrane protein 1 in Reed-Sternberg cells of Hodgkin's disease. Acta Med Okayama. 1996;50:267-270.
84. Fiumara P, Snell V, Li Y, Mukhopadhyay A, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98:2784-2790.
85. Horie R, Aizawa S, Nagai M, et al. A novel domain in the CD30 cytoplasmic tail mediates NF-κB activation. Int Immunol. 1998;10: 203-210.
86. Maniatis T. Catalysis by a multiprotein IκB kinase complex. Science. 1997;278:818-819.
87. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996;271: 12852-12858.
88. Lee SY, Lee SY, Kandala G, Liou ML, Liou HC, Choi Y. CD30/TNF receptor-associated factor interaction: NF-kappaB activation and binding specificity. Proc Natl Acad Sci U S A. 1996;93: 9699-9703.
89. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κB activation. J Biol Chem. 1997;272:2042-2045.
90. Boucher LM, Marengere LE, Lu Y, Thukral S, Mak TW. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun. 1997;233:592-600.
91. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17:1535-1542.
92. Hu HM, O'Rourke K, Boguski MS, Dixit VM. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem. 1994; 269:30069-30072.
93. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 1994;78:681-692.
94. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science. 1995;267:1494-1498.
95. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80:389-399.
96. Regnier CH, Tomasetto C, Moog-Lutz C, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem. 1995;270:25715-25721.
97. Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytoplasmic domain of CD40. FEBS Lett. 1995;358:113-118.
98. Song HY, Donner DB. Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumor necrosis factor. Biochem J. 1995;309:825-829.
99. Nakano H, Oshima H, Chung W, et al. TRAF5, an activator of NF-κB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem. 1996;271:14661-14664.
100. Ishida TK, Tojo T, Aoki T, et al. TRAF-5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci U S A. 1996;93:9437-9442.
101. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature. 1996;383:443-446.
102. Ishida T, Mizushima S, Azuma S, et al. Identification of TRAF6, a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem. 1996;271: 28745-28748.
103. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995; 269:1424-1427.
104. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2: distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem. 1996;271: 19935-19942.
105. Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 1997;11:2810-2821.
106. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumor necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999;18:3034-3043.
107. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351-2354.
108. Papoff G, Hausler P, Eramo A, et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem. 1999;274:38241-38250.
109. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288:2354-2357.
110. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815-818.
111. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.
112. Izban KF, Ergin M, Martinez RL, Alkan S. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol. 2000;13:1324-1331.
113. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr-virus-transformed lymphoid cells. Blood. 1999;93:617-623.
114. Arch RH, Gedrich RW, Thompson CB. Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem Biophys Res Commun. 2000;272:936-945.
115. Zapata JM, Krajewska M, Krajewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000;165:5084-5096.
116. Horie R, Watanabe T, Watanabe M, et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol. 2002;160:1647-1654.
117. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100: 2961-2969.
118. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999;189:1939-1946.
119. Croager EJ, Muir TM, Abraham LJ. Analysis of human and mouse promoter region of the non-Hodgkin's lymphoma-associated CD30 gene. J Interferon Cytokine Res. 1998;18:915-920.
120. Durkop H, Oberbarnscheidt M, Latza U, et al. The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter. J Pathol. 2000; 192:182-193.
121. Durkop H, Oberbarnscheidt M, Latza U, et al. Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30 (+) cell lines. Biochim Biophys Acta. 2001;1519:185-191.
122. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol. 2000;156:1723-1731.
123. Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol. 2000;156: 1479-1984.